Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jun 11;6(1):232.
doi: 10.1038/s41392-021-00661-w.

Exploiting a chink in the armor: engineering broadly neutralizing monoclonal antibodies for SARS-like viruses

Mirko Cortese  1 , Christopher J Neufeldt  2
Affiliations
Comment

Exploiting a chink in the armor: engineering broadly neutralizing monoclonal antibodies for SARS-like viruses

Mirko Cortese et al. Signal Transduct Target Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
a Isolated antibodies from a 2003 SARS survivor showed cross-neutralize activity for SARS-like viruses albeit with low potency. b Antibody engineering to increase binding affinity against SARS-CoV-2 S protein using deep mutagenesis and yeast library display. c Structural and molecular characterization of engineered antibodies displaying high neutralization breadth and potency against clade-1 sarbecoviruses. Figure created with BioRender.com
See this image and copyright information in PMC

Comment on

  • Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody.
    Rappazzo CG, Tse LV, Kaku CI, Wrapp D, Sakharkar M, Huang D, Deveau LM, Yockachonis TJ, Herbert AS, Battles MB, O'Brien CM, Brown ME, Geoghegan JC, Belk J, Peng L, Yang L, Hou Y, Scobey TD, Burton DR, Nemazee D, Dye JM, Voss JE, Gunn BM, McLellan JS, Baric RS, Gralinski LE, Walker LM. Rappazzo CG, et al. Science. 2021 Feb 19;371(6531):823-829. doi: 10.1126/science.abf4830. Epub 2021 Jan 25. Science. 2021. PMID: 33495307 Free PMC article.

References

    1. Rappazzo CG, et al. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. Science. 2021;371:823–829. doi: 10.1126/science.abf4830. - DOI - PMC - PubMed
    1. Davies, N. G. et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature, 593, 270–274 (2021). - PMC - PubMed
    1. Cruz-Teran C, et al. Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy. Adv. Drug Deliv. Rev. 2021;169:100–117. doi: 10.1016/j.addr.2020.12.004. - DOI - PMC - PubMed
    1. Weinreich DM, et al. REGN-COV2, a Neutralizing antibody cocktail, in outpatients with covid-19. N. Engl. J. Med. 2021;384:238–251. doi: 10.1056/NEJMoa2035002. - DOI - PMC - PubMed
    1. Hu, J. et al. Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies. Cell Mol. Immunol. 18, 1061–1063 (2021). - PMC - PubMed

Substances